‘Nvidia Accelerates AI Startup Investments, Nears Deal With Cloud Provider Lambda Labs’ – The Information

https://www.theinformation.com/articles/nvidia-accelerates-ai-startup-investments-nears-deal-with-cloud-provider-lambda-labsNvidia is known for its stranglehold over the market for the data center chips that power

https://www.theinformation.com/articles/nvidia-accelerates-ai-startup-investments-nears-deal-with-cloud-provider-lambda-labs

Nvidia is known for its stranglehold over the market for the data center chips that power ChatGPT and other artificial intelligence software. But in a matter of a few months, Nvidia has also become one of the biggest venture capital investors in an important class of customers who need its chips: cloud and AI software startups.

In the latest example, Nvidia is nearing a deal to take an equity stake in Lambda Labs, a startup that competes with Amazon Web Services and other established cloud providers in renting servers with Nvidia chips to other companies, according to people with knowledge of the situation. A deal, which could total $300 million in new capital and might value the company on paper at more than $1 billion including the new capital, would bring Nvidia closer to Lambda after the chip designer took a similar equity stake in CoreWeave, a Lambda rival.

 

Total
0
Shares
Related Posts
Read More

Equinor Pumps Millions Into Standard Lithium’s Sustainable Projects

Equinor ASA (NYSE:EQNR) ventures into the lithium market through a strategic $160 million partnership with Standard Lithium Ltd (NYSE:SLI), aiming to accelerate sustainable lithium projects in the Smackover Formation. Equinor secures a 45% ownership stake, pledging a $30 million initial payment and up to $130 million in contingent investments, bolstering Standard Lithium's financial outlook.

EQNR

Read More

Aurinia Pharmaceuticals Announced Departure of Executive Vice President, Research and Chief Medical Officer

On October 17, 2022, Aurinia Pharmaceuticals Inc. and Robert Huizinga, PhD RN, CNeph(C), our Executive Vice President, Research and Neil Solomons, M.D., our ChiefMedical Officer, mutually agreed that Dr. Huizinga and Dr. Solomons would cease their employment with Aurinia, each effective October 31, 2022.We expect to enter into separation agreements with Dr. Huizinga and Dr.

AUPH